Efficacy and safety of telitacicept, a BLyS/APRIL dual inhibitor, in the treatment of IgA nephropathy: a retrospective case–control study
Telitacicept may be a safe and effective treatment for IgAN, offering reductions in proteinuria and increases in eGFR similar to conventional IS therapy. After a 24-week follow-up, the incidence of adverse events was lower for telitacicept than for conventional IS therapy.
Authors
- Yi Fan (ORCID: https://orcid.org/0000-0001-5544-2867)
- Meng Wang (ORCID: https://orcid.org/0000-0003-4523-6263)
- Yao Li (ORCID: https://orcid.org/0000-0003-2986-8789)
- Jianfei Ma (ORCID: https://orcid.org/0000-0002-4806-5888)
Institutions
- First Hospital of China Medical University (CN)
- China Medical University (CN)
Publication Details
- Journal
- Clinical Kidney Journal
- Published
- 2024-09-13
- DOI
- https://doi.org/10.1093/ckj/sfae285
- Citations
- 19
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 6.44